Natriumphosphat Braun (Disodium Phosphate Dodecahydrate, Sodium Dihydrogen Phosphate Dihydrate)

The sodium phosphate salts dissociate in plasma to release phosphate ions, which act as buffers in the bicarbonate system and serve as essential substrates for cellular metabolism. By increasing extracellular phosphate, the solution helps normalize pH, supports ATP production, and contributes to bone mineralization while maintaining overall electrolyte homeostasis.

The dose of Natriumphosphat Braun is individualized by the prescribing clinician based on the patient’s serum phosphate level, renal function, and overall fluid balance. Healthcare professionals calculate the appropriate volume and infusion rate to achieve the desired therapeutic effect while avoiding over‑correction.

Safety data for Natriumphosphat Braun in pregnancy and lactation are limited. The product should only be used if the potential benefit to the mother outweighs any possible risk to the fetus or infant, and the decision must be made by a qualified healthcare provider after careful evaluation.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed), and required import documentation.

Natriumphosphat Braun provides a sterile, ready‑to‑use intravenous formulation that delivers both disodium phosphate and sodium dihydrogen phosphate, offering balanced sodium and phosphate loads. Compared with oral phosphate salts, it allows rapid correction of severe hypophosphatemia and precise control of infusion rates, which is advantageous in critical‑care and dialysis settings.

Store the solution at ambient temperature, preferably below 25 °C, in its original sealed container. Protect it from moisture, direct sunlight, and extreme temperature fluctuations. Do not freeze the product, and inspect the vial for particulate matter or discoloration before use.

The solution is administered intravenously, typically via a peripheral or central line. The infusion rate is determined by the prescribing clinician and may be adjusted based on real‑time laboratory monitoring of serum phosphate, calcium, and acid‑base status. Infusion should be performed using aseptic technique.

Serious risks include severe electrolyte disturbances such as hyperphosphatemia, hypocalcemia, or metabolic alkalosis, which can lead to cardiac arrhythmias or neuromuscular complications. Rarely, anaphylactic reactions or severe hypotension may occur, especially with rapid infusion. Continuous monitoring is essential to detect and manage these events promptly.

Patients with known hypersensitivity to any component of the formulation, uncontrolled hyperphosphatemia, severe hypercalcemia, or those receiving incompatible calcium‑containing IV solutions should not receive Natriumphosphat Braun. Clinicians should also exercise caution in individuals with advanced renal failure or severe cardiac disease.